Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768845 | 0.84 | BACE1 (0.36) | BACE1 | |
| SCHEMBL7993286 | 0.84 | BACE1 (0.41) | MAPTSMN1; SMN2BACE1GAA | |
| SCHEMBL9939055 | 0.81 | RECQL (0.50) | MAPTSMN1; SMN2 | |
| SCHEMBL16701535 | 0.81 | BACE1 (0.37) | MAPTSMN1; SMN2BACE1ALDH1A1GAA | |
| SCHEMBL1403176 | 0.80 | BACE1 (0.40) | MAPTSMN1; SMN2BACE1GAA | |
| SCHEMBL1403152 | 0.80 | BACE1 (0.40) | MAPTSMN1; SMN2BACE1ALDH1A1GAA | |
| SCHEMBL16701763 | 0.79 | MAPT (0.32) | MAPTSMN1; SMN2BACE1 | |
| SCHEMBL7992161 | 0.79 | BACE1 (0.39) | MAPTSMN1; SMN2BACE1ALDH1A1GAA | |
| SCHEMBL14698626 | 0.79 | MAPT (0.32) | MAPTSMN1; SMN2BACE1 | |
| SCHEMBL695478 | 0.78 | BACE1 (0.38) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2020-02-25 | — | — | US | disclosed |
| US-20180251466-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE, LTD. (KY) | 2018-09-06 | — | — | US | disclosed |
| US-10005782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BEIGENE, LTD. (KY) | 2018-06-26 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-20170073349-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2017-03-16 | — | — | US | disclosed |
| US-9556188-B2 | Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators | BEIGENE, LTD. (KY) | 2017-01-31 | — | — | US | disclosed |
| EP-2989106-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE LTD (KY) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016173948-A1 | INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | WO | disclosed |
| US-9447106-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BEIGENE, LTD. (KY) | 2016-09-20 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
| EP-2989106-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Beigene, Ltd. (KY) | 2016-03-02 | — | — | EP | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251466-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
| US-10005782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | MAPT 4445/4885SMN1; SMN2 4769/4885BACE1 2337/4885 |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
| US-20170073349-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BTK, WEE1, LYN | MAPT 4445/4885SMN1; SMN2 4769/4885BACE1 2337/4885 |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | MAPT 4445/4885SMN1; SMN2 4769/4885BACE1 2337/4885 |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | MAPT 4821/4885SMN1; SMN2 4780/4885BACE1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.